Anti-Diabetic Drugs Thwart the Hepatitis C Virus | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Boceprevir Meets Key Hep C Goals

Back to News Homepage
Next

Appetite Hormone Could Inhibit HCV-Related Fibrosis

Anti-Diabetic Drugs Thwart the Hepatitis C Virus

The Editors at Hepatitis Central
August 6, 2010

Print this page

By analyzing the role of the AMP kinase enzyme in Hepatitis C viral proliferation, University of Leeds researchers have discovered that certain traditional diabetes drugs prevent Hepatitis C viral replication.

New Use for Old Drugs in Treating Hepatitis C?

August 5, 2010

Research led by the University of Leeds has found drugs such as anti-diabetic drug Metformin and AICAR, used to combat obesity, can prevent the hepatitis C virus from replicating in the body. Hepatitis C virus affects an estimated three per cent of the world’s population and there are four million carriers of the virus in Europe alone. The virus affects the liver and recovery rates are low: only around 40 % of hepatitis C sufferers will fully recover, with others developing cirrhosis and in many cases, liver cancer.

“We’re very excited about these findings,” said Professor Mark Harris from the University’s Faculty of Biological Sciences. “These drugs are already on the market, and whilst substantial clinical trials still need to take place before they can be used to treat hepatitis C infection, we think it could be an enormous step forward in the battle against the virus.”

Continue reading this entire article:
http://www.labmate-online.com/news/news-and-views/5/news/new_use_for_old_drugs_in_treating_hepatitis_c/11108/

No Comments - be the first!
Share
Share
Previous

Boceprevir Meets Key Hep C Goals

Back to News Homepage
Next

Appetite Hormone Could Inhibit HCV-Related Fibrosis

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.